Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Microscopic spheres of calcium phosphate linked to AMD development

Microscopic spheres of calcium phosphate have been linked to the development of age-related macular degeneration (AMD), a major cause of blindness, by UCL-led research.

21 Jan 2015

Tiny lumps of calcium phosphate may trigger age-related macular degeneration

New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness.

20 Jan 2015

Iron accumulation in human tissues may contribute to the aging process

It's been known for decades that some metals, including iron, accumulate in human tissues during aging and that toxic levels of iron have been linked to neurologic diseases, such as Parkinson's. Common belief has held that iron accumulation happens as a result of the aging process.

17 Jan 2015

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years.

8 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Scientific collaboration reveals encouraging insight on AMD disease

Insilico Medicine along with scientists from Vision Genomics and Howard University shed light on AMD disease, introducing the opportunity for eventual diagnostic and treatment options.

12 Dec 2014

Exudation-free period key to cataract surgery success in AMD

Cataract surgery can benefit patients with exudative age-related macular degeneration previously treated with anti-vascular endothelial growth factors if they have been treated and are exudation-free for more than 12 months, study findings indicate.

11 Dec 2014

Optical coherence tomography methods comparable for AMD assessments

There is good accordance between spectral-domain and time-domain optical coherence tomography image assessments of eyes treated for neovascular age-related macular degeneration, show study findings.

11 Dec 2014

OCT enhances neovascular subtype detection in AMD

Researchers recommend the inclusion of optical coherence tomography anatomic classification with fluorescein angiography grading to identify initial neovascular lesion subtypes in newly diagnosed age-related macular degeneration.

11 Dec 2014

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Scientists have developed a new light-sensitive film that could one day form the basis of a prosthetic retina to help people suffering from retinal damage or degeneration. Hebrew University of Jerusalem researchers collaborated with colleagues from Tel Aviv University and Newcastle University in the research, which was published in the journal Nano Letters.

5 Dec 2014

Research to Prevent Blindness, IRRF partner to advance knowledge about AMD

Research to Prevent Blindness, the leading eye research foundation, is partnering with the International Retinal Research Foundation to advance knowledge about age-related macular degeneration (AMD) through novel stem cell research.

5 Dec 2014

New study describes revolutionary novel device that has potential to treat eye diseases

The aging process affects everything from cardiovascular function to memory to sexuality. Most worrisome for many, however, is the potential loss of eyesight due to retinal degeneration.

3 Dec 2014

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock.

2 Dec 2014

Researchers find that human eye can sense invisible infrared light under certain conditions

Any science textbook will tell you we can't see infrared light. Like X-rays and radio waves, infrared light waves are outside the visual spectrum.

2 Dec 2014

Success for nurse practitioner-delivered intravitreal injection service for wAMD

Well-trained nurse practitioners can successfully provide an injection service for the treatment of wet age-related macular degeneration with ranibizumab, an audit shows.

1 Dec 2014

Second treated eyes with nAMD functionally more important than first eyes

A real-world study of the characteristics of second treated eyes in patients with neovascular age-related macular degeneration given ranibizumab in the UK National Health Service has shown that these eyes start off with better baseline visual acuity than first treated eyes and, despite a poor response to therapy, maintain this advantage.

1 Dec 2014

VE-PTP potential treatment target for retinal and choroidal vascular diseases

Targeting vascular endothelial-protein tyrosine phosphatase, which negatively regulates TIE2 activation, could help to stabilise retinal and choroidal blood vessels, researchers report.

1 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

HIV drugs could be harnessed to treat leading cause of blindness

An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure.

27 Nov 2014